drugset / Trial / NCT00821444

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

NCT00821444

Phase 1 Completed 11 enrolled Viatris Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

Commercial ziprasidone capsules show a large increase in bioavailability with food. The formulation tested in this study aims to reduce or eliminate that increase.

Timeline

Start
2009-01
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject B16 Unknown 40 mg
Comparator Ziprasidone Small molecule 40 mg

Indications

No indication recorded.